Canagliflozin: Real World Experience

Slides:

Advertisements

Similar presentations

Reductions in Regimen Distress Are Associated With Improved Management and Glycemic Control Over Time Featured Article: Danielle Hessler, Lawrence Fisher,

Advertisements

Valsartan Antihypertensive Long-Term Use Evaluation Results

Factors Associated With Weight Gain in People With Type 2 Diabetes Starting on Insulin Featured Article: Beverley Balkau, Philip D. Home, Maya Vincent,

Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2011.

Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections.

Journal Club Alcohol, Other Drugs, and Health: Current Evidence January–February 2010.

Barriers to Diabetes Control Mark E. Molitch, MD.

Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.

Individualizing Targets and Tactics for High- Risk Patients With Type 2 Diabetes Practical lessons from ACCORD and other cardiovascular trials Featured.

Rapid Rise in Hypertension and Nephropathy in Youth With Type 2 Diabetes The TODAY clinical trial Featured Article: TODAY Study Group* Diabetes Care Volume.

Quality of life improves after patients switch to biphasic insulin aspart 30/70 (BIAsp 30): IMPROVE™ Study data from 39,015 patients M. Benroumpi 1, T.

Racial Differences in the Impact of HMO Coverage of Diabetes Blood Glucose Monitors on Self-Monitoring Connie A. Mah, M.S. Department of Ambulatory Care.

An analysis of early insulin glargine added to metformin with or without sulfonylurea: impact on glycaemic control and hypoglycaemia.

Ali Ardestani, David Rhoads, Ali Tavakkoli

Basal Bolus: The Strategy for Managing All Diabetes Fall, 2003 Paul Davidson, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.

The Obesity/Diabetes Epidemic: Adiposopathy & ‘Obesity’- The New Disease! Weight Management in Obesity and DM: Emphasis on New Medical Therapies Stan Schwartz.

A Diabetes Outcome Progression Trial

Therapy of Type 2 Diabetes Mellitus: UPDATE

The Diabetic Retinopathy Clinical Research Network Effect of Diabetes Education During Retinal Ophthalmology Visits on Diabetes Control (Protocol M) 11.

Adding Prandial Insulin to Basal Insulin: Key Challenges

Int J Clin Pract, December 2013, 67, 12,

An initiative of South Asian Federation of Endocrine Societies (SAFES)

1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.

SGLT-2 Inhibitors Surprising New Information. Logic for SGLT-2 Inhibition : My Own Comment on MOA- Logic for Benefit: 1.Kidney is an ‘active player’ in.

Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea A.

Improving Adherence in Type 2 Diabetes Mellitus ALLISON PETZNICK DO NOMS FAMILY MEDICINE SANDUSKY, OH.

Supported by Virtual Poster Hall: Summary Slides Professor Stephan Matthaei Tuesday, September 15 th This Virtual Poster Hall session explores the relationship.

Carina Signori, DO Journal Club August 2010 Macdonald, M. et al. Diabetes Care; Jun 2010; 33,

HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.

Dr Mohammed Babsail, Dr Bhavin Bakrania

Glycemia Treatment Strategies Used In ACCORD

Taieb V, et al. Value Health Nov;18(7):A598.

2012 ADA Clinical Practice Guidelines Therapies for DM- Type 2

THE EFFICACY GAP BETWEEN CLINICAL TRIAL AND

Key publication slides

Key publication slides

Diabetes and Obesity Journal Club Carina Signori, D.O., M.P.H.

Alcohol, Other Drugs, and Health: Current Evidence

Neal B, et al. Diabetes Care 2015;38:403–411

Therapy of Type 2 Diabetes Mellitus: UPDATE

Design of a multicohort evaluation of statin adherence after the start of 2 cost-sharing policies Sebastian Schneeweiss, et al. Circulation 2007;115:

Adherence to and persistence with oral antidiabetic medication were evaluated in a sample of 238,372 patients with type 2 diabetes initiating a dipeptidyl.

Empagliflozin (Jardiance®)

MK-0431 P051 PDT APPROVED 4/10/09 11/13/2018 2:49 PM

Updates on Emerging GLP-1 Receptor Agonists

Patient Case Discussions in T2D: What Intensification Plan Is Best?

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Sodium-glucose co-transporter 2 (SGLT2) inhibitors work by blocking the reabsorption of filtered glucose in the kidneys. This leads to glucosuria and improved.

Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.

Looking Beyond Glucose Control: Multifactorial Management of Type 2 Diabetes.

Insights into Insulin Treatment Challenges: Real-World Evidence and Clinical Trial Data.

Options for Combination Therapy in Type 2 Diabetes: Comparison of the ADA/EASD Position Statement and AACE/ACE Algorithm Timothy Bailey, MD The American.

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Observational Studies vs. Randomized Controlled Trials (RCT)

The Research Question Does self monitoring of blood glucose (SMBG) in patients with non-insulin treated type 2 diabetes improve glycemia or quality of.

New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.

SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?

Side-by-side comparison of change in A1C with canagliflozin versus DPP-4 inhibitors in randomized clinical trials and the real-world study. *Data are LS.

Improving Overall Health

Guidelines for Initiation of Therapy

Managing Blood Pressure

Range of mean changes from baseline in A1C in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor agonists.

Cumulative incidence of monotherapy failure in matched samples of sulfonylurea (n=717) versus metformin (n=3585), when followed for up to 5.5 years. Cumulative.

Diabetes Self-Management Education and Support: Component of Standard Diabetes Care 1, 2 “… Ongoing patient self-management education and support are.

Observed RW, modeled, and published trial estimates of HbA1c change from baseline. Observed RW, modeled, and published trial estimates of HbA1c change.

Treatment response patterns and effect size over time in exclusively placebo-controlled trials. Treatment response patterns and effect size over time in.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Fig. 1. Antihyperglycemic therapy algorithm for adult patients with type 2 diabetes mellitus (T2DM). The algorithm stratifies the choice of medications.

Presentation transcript:

Canagliflozin: Real World Experience

Buysman EK, et al. BMC Endocr Disord. 2015 Nov 2;15(1):67.

Methods Retrospective cohort study of data obtained from a large health plan database The data of adult T2DM patients (≥18 years) taking Canagliflozin between April and October 2013 were included Changes in glycemic control were evaluated, along with characteristics of enrolled patients & changes in treatment patterns Buysman EK, et al. BMC Endocr Disord. 2015 Nov 2;15(1):67.

Canagliflozin usage with respect to other Antihyperglycemic Agent (AHA) 20% patients taking Cana monotherapy 50% patients taking Cana with 2 or more other AHA 30% patients taking Cana as add on to 1 AHA Buysman EK, et al. BMC Endocr Disord. 2015 Nov 2;15(1):67.

From Clinical Trial to Clinical Practice: Higher the baseline HbA1c better the reduction with Cana Buysman EK, et al. BMC Endocr Disord. 2015 Nov 2;15(1):67.

From Clinical Trial to Clinical Practice: Higher the baseline HbA1c better the reduction with Cana Greatest reduction in HbA1c in patients with the highest baseline HbA1c levels Buysman EK, et al. BMC Endocr Disord. 2015 Nov 2;15(1):67.

From Clinical Trial to Clinical Practice : AHA discontinuations after addition of Canagliflozin 20% patients appeared to discontinue at least one of the AHAs from their baseline regimen A trend toward lower AHA use for metformin, SUs, insulin, DPP4i, GLP-1 agonists and thiazolidinediones, ranging from −11 % to −16 % A high median adherence of 86% was seen with Canagliflozin* *in patients with two or more canagliflozin fills

High Adherence with Canagliflozin: Possible reasons Canagliflozin can help to increase motivation and self-esteem in patients with T2DM as in addition to good glycemic control it also offers clinical benefits i.e., body wt. reduction and lowering of BP This can lead to greater motivation to conform to healthy behaviors including medication-taking Such benefits can improve the overall effectiveness of therapy by creating a positive cycle of well-being that motivates patients to implement and sustain the necessary lifestyle changes that are an important feature of diabetes self- management Buysman EK, et al. BMC Endocr Disord. 2015 Nov 2;15(1):67.

Conclusion In this real-world setting, with Canagliflozin Significant improvements in A1C were observed in the first 6 months of Canagliflozin usage The results were consistent with those observed in the RCTs A substantial proportion of patients were able to attain their A1C goals A trend to lower other AHA use was observed, indicating Canagliflozin could potentially lead to cost offsets in treating T2DM Buysman EK, et al. BMC Endocr Disord. 2015 Nov 2;15(1):67.